hotspot -WSS

hotspot

author：explore 2025-09-28 21:05:25 - browse：319

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Harvard's Jason Buenrostro wins MacArthur grant for genetics work

focus

knowledge

WSS

FDA clears Verve to begin U.S. study of gene

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Many immigrants are left out of maternal health programs

Campaign finance charge dropped from case against Sam Bankman

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

Wikipedia

hotspot

hotspot

Cancer drug shortages should be causing more outrage

House GOP plan to stem drug shortages differs from Democrats’

Sports medicine is finally prioritizing gender equality

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Novavax promises a turnaround & Lilly roils the obesity market

House GOP plan to stem drug shortages differs from Democrats’

Hepatitis C has a cure — but many Americans still lack access to it

Is there really a nursing shortage in the U.S.?

Guidelines to prevent youth baseball injuries need more muscle

Results on Novartis prostate cancer therapy could expand its use

knowledge

Roivant's CEO is a star, but biotech's black hole persists

House GOP plan to stem drug shortages differs from Democrats’

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Is there really a nursing shortage in the U.S.?

HCA says smaller share of spending going to labor

hotspot

focus

knowledge

focus